CFAR Network of Integrated Clinical Systems (CNICS)

Presented by Michael Saag of the UAB Center for AIDS Research presents on the CFAR Network of Integrated Clinical Systems (CNICS).  Please see below for registration details.

Registration Information

All webinars will be held on the fourth Monday of every month, and will be hosted by the UNC Center for AIDS Research in collaboration with the NC Aids Education and Training Center (NCAETC).

 

DC Cohort HIV-1 NGS – Results and Pipeline Used for DRM Analyses

Webinar presented by Jeanne Jordan of the DC Center for AIDS Research.  Please see below for registration details.

Registration Information

All webinars will be held on the fourth Monday of every month, and will be hosted by the UNC Center for AIDS Research in collaboration with the NC Aids Education and Training Center (NCAETC).

 

2017 CFAR Developmental Award Webinar – March 28

The UNC Center For AIDS Research (CFAR) Developmental Core will be conducting a webinar on Tues., March 28th, at 9 am EDT.  This free webinar will focus on applying for and implementing a 2017 CFAR Developmental Award, and will address the application process, NIH requirements, necessary documents, and more.  Both domestic and international research will be addressed and questions are welcomed.  You may send your questions to us beforehand or ask them via text at the time of the webinar.

To register, email cathy@unc.edu.  We will send out directions on how to attend the webinar at the time of your registration.

HPTN 083 Webinar – Give PrEP a Shot!

The HIV Prevention Trials Network (HPTN) has launched a new study, HPTN 083, to evaluate whether injectable cabotegravir (CAB) can safely protect cisgender men who have sex with men (MSM) and transgender women (TGW) who have sex with men from acquiring HIV as well as Truvada, an oral tablet taken daily for HIV prevention, also known as pre-exposure prophylaxis (PrEP). If found to be safe and effective for HIV PrEP, injectable CAB may be easier for some people to adhere to than daily oral Truvada.
 
This webinar will provide a comprehensive overview of HPTN 083 by explaining why the study is being done and what will happen during the study. Additionally, the HPTN’s commitment to community participation at all levels of research will be described by detailing the many community involvement and engagement activities used in preparation for the study and now during its implementation.
 
For more information about the HIV Prevention Trials Network and HPTN 083, please visit http://www.HPTN.org.

Women and HIV Cure: Barriers and Facilitators to Women’s Participation in Cure Research

A Three-Part Webinar Series Presented by the Women’s HIV Research Collaborative (Part 3)

Thursday, November 17

In recent years, the scientific community has made great strides toward finding a cure for HIV. Activists and advocates are rightfully excited about these developments, but many questions remain about what a cure will entail and how the science might reach different populations and communities. While cure research has generated exciting results, it is crucial that these results include and are relevant to all people with HIV. Women, however, are often excluded or otherwise left out of HIV cure efforts. The members of the Women’s HIV Research Collaborative (WHRC) believe that cure research must include women—cisgender and transgender alike—in order to produce results that are applicable and meaningful to women. In this spirit of sisterhood and the meaningful involvement of people with HIV, the WHRC has assembled a diverse group of expert women working in community advocacy, biomedical research, and bioethics to guide us through this three-part webinar series.

Women and HIV Cure: What Cure Means to Women, What Women Mean to Cure

A Three-Part Webinar Series Presented by the Women’s HIV Research Collaborative (Part 2)

Tuesday, October 25

In recent years, the scientific community has made great strides toward finding a cure for HIV. Activists and advocates are rightfully excited about these developments, but many questions remain about what a cure will entail and how the science might reach different populations and communities. While cure research has generated exciting results, it is crucial that these results include and are relevant to all people with HIV. Women, however, are often excluded or otherwise left out of HIV cure efforts. The members of the Women’s HIV Research Collaborative (WHRC) believe that cure research must include women—cisgender and transgender alike—in order to produce results that are applicable and meaningful to women. In this spirit of sisterhood and the meaningful involvement of people with HIV, the WHRC has assembled a diverse group of expert women working in community advocacy, biomedical research, and bioethics to guide us through this three-part webinar series.

CUREiculum Webinar Series: Early ART

The CUREiculum is a suite of tools that provides simple, accessible information on HIV cure research. As part of the effort to increase research literacy around cure, the CUREiculum team, a collaboration of community educators, researchers and advocacy organizations, will be presenting a webinar series that focus on issue-specific topics crucial to understanding the research landscape.

Early ART
Thursday, April 2nd at 11 am ET

Dr. Jintanat Ananworanich, Associate Director for Therapeutics Research at the U.S. Military HIV Research Program (MHRP) of the Walter Reed Army Institute for Research (WRAIR), will present the scientific mechanisms of early treatment and explain how it relates to HIV cure research. Administering early antiretroviral therapy can have a significant impact on limiting the reservoir- the cells that contain non-replicating HIV- in an HIV-positive individual. Starting ART very early after HIV infection has been linked to very low viral loads and even to apparent “remission” (periods of no detectable viral load)

Register here for webinar details!

For more information, please contact Jessica or Karine.

CUREiculum Webinar Series: Latency Reversing Agents

The CUREiculum is a suite of tools that provides simple, accessible information on HIV cure research. As part of the effort to increase research literacy around cure, the CUREiculum team, a collaboration of community educators, researchers and advocacy organizations, will be presenting a webinar series that focus on issue-specific topics crucial to understanding the research landscape.

Latency Reversing Agents
Thursday March 26th, 4 pm ET

This webinar will feature Dr. David Margolis, Principal Investigator of the CARE Collaboratory at University of North Carolina at Chapel Hill, and Dr. Sharon Lewin member of the DARE Collaboratory and Director of the Infectious Disease department at Monash University. Latency reversing agents are biological compounds used to “wake up” HIV infected cells from their resting state in the body. The drugs are used as the “kick”, the first in a two phase strategy often called “kick and kill”. Both researchers will discuss what latency reversing agents are and how the research might contribute to a combination curative strategy.

Register here for webinar details!

For more information, please contact Jessica or Karine.

CUREiculum Webinar Series: Stakeholder Engagement in Cure Research

The CUREiculum is a suite of tools that provides simple, accessible information on HIV cure research. As part of the effort to increase research literacy around cure, the CUREiculum team, a collaboration of community educators, researchers and advocacy organizations, will be presenting a webinar series that focus on issue-specific topics crucial to understanding the research landscape.

Stakeholder Engagement in Cure Research
Friday March 13th, 11 am ET

This webinar, led by Jessica Handibode of AVAC, will discuss how the Good Participatory Practice (GPP) guidelines, developed by UNAIDS and AVAC, can be applied to HIV cure research. GPP provides trial funders, sponsors and implementers with systematic guidance on how to effectively engage with all stakeholders. Drawing from the literature and past HIV prevention trials, the webinar will explore the history and importance of engaging community stakeholders early in the research process.

Register here for webinar detail!

For more information, please contact Jessica or Karine.

World AIDS Day Clinical Trials Twitter Chat and ‘HIV Clinical Trials: A Year in Review’ Webinar

webinarWorld AIDS Day Clinical Trials Twitter Chat and an ‘HIV Clinical Trials: A Year in Review’ Webinar

Featuring presentations by Jim Maynard of the HIV Vaccine Trials Network, Jonathan Lucas of the HIV Prevention Trials Network and Clare Collins of the Microbicide Trials Network

WAD Clinical Trials Twitter Chat
Date: Wednesday November 19, 2014
Time: 11:00 am
Event Hashtag: #ClinicalTrialsChat

HIV Clinical Trials: A Year in Review Webinar
Date: Wednesday November 19, 2014
Time: 1:00 pm

Register here.